Four different concentrations of Dactylis glomerata allergen extract, positive control and negative control

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Allergy to Grass Pollen (Dactylis Glomerata)

Drug Information

Target Indication

Allergy to Grass Pollen (Dactylis Glomerata)

Clinical Trial

Last updated: 1/24/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

LRVIY

Laboratorios Farmaceuticos Rovi, S.A./ADR

Related Pipeline

Allergic Rhinoconjunctivitis

Osteoarthritis of Knee

Alopecia

Influenza, Human

Arterial Hypertension